California Supreme Court overturns ruling, clears Gilead of liability over HIV drug delay

In a 6-1 vote, the state's top court nullified an appellate judgment that could have held Gilead accountable for delaying a newer HIV treatment. Plaintiffs—over 24,000 patients—asserted the company’s product-pipeline choices caused unnecessary kidney injury and bone loss from an older drug. The ruling removes legal pressure on the firm and raises concerns that pharmaceutical development may now be less constrained by liability fears.